Comparison of Femoropopliteal Bypass and Superficial Femoral Artery Stenting for Treating Femoral Artery Occlusive Disease

대퇴동맥 폐색증에서 대퇴동맥-슬와동맥 우회술과 대퇴동맥 스텐트 삽입술의 비교

  • Lee, Gun (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University) ;
  • Lim, Chang-Young (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University) ;
  • Kim, Man Deuk (Department of Diagnostic Radiology, Bundang CHA General Hospital, College of Medicine, Pochon CHA University) ;
  • Lee, Hyeon-Jae (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University)
  • 이건 (포천중문의과대학교 분당차병원 흉부외과학교실) ;
  • 임창영 (포천중문의과대학교 분당차병원 흉부외과학교실) ;
  • 김만득 (포천중문의과대학교 분당차병원 영상의학교실) ;
  • 이헌재 (포천중문의과대학교 분당차병원 흉부외과학교실)
  • Received : 2008.09.16
  • Accepted : 2008.10.14
  • Published : 2009.02.05

Abstract

Background: The goal of this study was to compare the patency and complications of femoropopliteal bypass with superficial femoral artery stenting for patients with atherosclerotic superficial femoral artery occlusive disease. Material and Method: Between July 2005 and July 2008, we reviewed 29 femoropopliteal bypass procedures (24 patients) with prosthetic grafts (the bypass group) and 19 superficial femoral artery stentings (15 patients) with nitinol stent (the stent group). There were 35 male patients (89.7%) and the mean age of the patients was 69.2 years (range: 48~84). The number of patients who had DM, hypertension and a smoking history was 25 patients (64.1%), 17 patients (43.6%) and 30 patients (76.9%), respectively. 23 (59.0%) patients had skin ulceration or tissue gangrene at admission. Result: There were 27 cases (93.0%) of TASC C&D lesion in the bypass group and 16 cases (84.2%) of TASC A&B lesion in the stent group. There were significant differences for the indications for a procedure between the two groups (p<0.01). The primary patency rates at 6 months, 12 months and 24 months were 91.9%, 79.7% and 79.7% for the bypass group and 93.3%, 86.2% and 86.2% for the stent group, respectively. There were no statistical difference between the two groups (p=0.48). Conclusion: There were no significant differences in the outcome between two groups. TASC C&D lesion and failed intervention therapy should be treated with femoropopliteal bypass surgery, and TASC A&B lesion and the high-risk patients should be treated with femoral artery stent insertion.

배경: 동맥경화에 의한 표재성 대퇴동맥의 치료방법 중에서 인조혈관을 이용한 대퇴동맥-슬와동맥 우회술과 대퇴동맥내 스텐트 삽입술의 개존율과 합병증 등을 비교하고자 하였다. 대상 및 방법: 2005년 7월 부터 2008년 7월까지 24명의 환자에서 29예의 인조혈관을 이용한 대퇴동맥-슬와동맥 우회술(우회술군)과 15명의 환자에서 19예의 대퇴동맥 스텐트 삽입술(스텐트군)을 대상으로 조사하였다. 전체환자 중 남자가 35명으로 89.7%를 차지하였고, 평균 연령은 69.2세(48세부터 84세까지)였다. 당뇨병, 고혈압, 흡연력은 각각 21명(53.8%), 16명(41.0%), 25명(64.1%)이었다. 내원 당시 피부 궤양이나 조직의 괴사가 있었던 경우는 23예(59.0%)였다. 결과: 우회술군은 TASC C와D의 병변이 27예로 93%였고, 스텐트군은 TASC A와 B의 병변이 16예로 84.2%였으며 각 치료방법의 적응증에 차이가 있었다(p<0.01). 우회술군의 6개월, 12개월, 24개월의 일차개존율은 91.9%, 79.7%, 79.7%였고, 스텐트군의 6개월, 12개월, 24개월의 일차개존율은 93.3%, 86.2%, 86.2%였으며 양 치료방법 간에 개존율의 차이는 없었다(p=0.48). 결론: 두 치료방법간에 성적의 차이는 없었다. 따라서 스텐트 시술에 실패한 경우나 TASC C와 D의 병변은 대퇴동맥-슬와동맥 우회술을, 고위험군의 환자나 TASC A와 B의 병변은 대퇴동맥 스텐트 시술을 시행하는 것이 좋겠다.

Keywords

References

  1. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1-296 https://doi.org/10.1016/S0741-5214(00)81002-2
  2. Surowiec SM, Davis MG, Eberly SW, et al. Percutaneous angioplasty and stenting of the superficial femoral artery. J Vasc Surg 2005;41:269-78 https://doi.org/10.1016/j.jvs.2004.11.031
  3. Patterson R, Pinto B, Marcus B, et al. Value of a supervised exercise program for the therapy of arterial claudication. J Vasc Surg 1997;25:312-9 https://doi.org/10.1016/S0741-5214(97)70352-5
  4. Dawson D, Cutler B, Meissner M, et al. Cilostazol has beneficial effects in treatment of intermittent claudication. Circulation 1998;98:678-86 https://doi.org/10.1161/01.CIR.98.7.678
  5. Dormandy T, Heeck L, Vig S. Peripheral arterial occlusive disease. Clinical data for decision making. Semin Vasc Surg 1999;12:93-162
  6. Sala F, Hassen-Khodja R, Lecis A, et al. Long-term outcome of femoral above-knee popliteal artery bypass using autologous saphenous vein versus expanded polytetrafluoroethylene grafts. Ann Vasc Surg 2003;17:401-7 https://doi.org/10.1007/s10016-003-0019-9
  7. Klinkert P, Schepers A, Burger DH, et al. Vein versus polytetrafluoroethylene in above-knee femoropopliteal bypass grafting, five year results of a randomzed controlled trial. J Vasc Surg 2003;37:149-55 https://doi.org/10.1067/mva.2002.86
  8. Post S, Kraus T, Muller-Reinartz U, et al. Dacron vs polytetrafluoroethylene grafts for femoro-popliteal bypasses; a prospective randomized multicentre trial. Eur J Vasc Surg 2001;22:226-31 https://doi.org/10.1053/ejvs.2001.1424
  9. Sabeti S, Shillinger M, Amighi J, et al. Primary patency of femoropopliteal arteries treated with Nitinol versus stainless steel self expanding stents: propensity score-adjusted analysis. Radiology 2004;232:516-21 https://doi.org/10.1148/radiol.2322031345
  10. Schermerhorn ML, Cronenwett JL, Baldwin JC. Open surgical repair versus endovascular therapy for chronic lower-extremity occlusive disease. Annu Rev Med 2003;54: 269-83 https://doi.org/10.1146/annurev.med.54.101601.152509
  11. Park KH. Endovascular treatment of iliac & femoral artery occlusive disease. J Korean Soc Vasc Surg 2008;24:72-5
  12. Matsi PJ, Manninen HI, Vanninen RL, et al. Femoropopliteal angioplasty in patients with claudication: primary and secondary patency in 140 limbs with 1-3 year follow-up. Radiology 1994;191:727-33 https://doi.org/10.1148/radiology.191.3.8184053